| Introduction | | | | Business description 34 |
| This report analyzes the global pharmaceutical market | | | | SWOT analysis 35 |
| in terms of market size, key drivers and resistors, | | | | Strengths 35 |
| trends and competitive positioning. It includes profiles of | | | | Weaknesses 36 |
| the top ten companies in the industry along with 5-year | | | | Opportunities 37 |
| financial analysis and in-depth SWOT analysis. | | | | Threats 38 |
| Scope | | | | Recent developments 38 |
| *Performance of the global pharmaceutical market on | | | | F. Hoffmann-La Roche 40 |
| the basis of sales, volume and respective growth | | | | Company overview 40 |
| patterns over the past five years | | | | Business description 40 |
| *Obtain descriptive profiles of the top ten leading | | | | SWOT analysis 41 |
| players including strategic initiatives undertaken in the | | | | Strengths 41 |
| last 12 months | | | | Weaknesses 41 |
| *Analysis of the Strengths, Weaknesses, Opportunities | | | | Opportunities 42 |
| and Threats of the top 10 pharmaceutical companies | | | | Threats 43 |
| along with business overview and financials | | | | Recent developments 43 |
| *Benchmark the performance of the top 10 players for | | | | Novartis 45 |
| the past five years; includes revenue comparison, | | | | Company overview 45 |
| profitability analysis, industry-specific ratios | | | | Business description 45 |
| Highlights | | | | SWOT analysis 46 |
| The global pharmaceutical market generated total | | | | Strengths 46 |
| revenues of $615.1 billion in 2008, representing a | | | | Weaknesses 47 |
| compound annual growth rate (CAGR) of 4.7% for | | | | Opportunities 47 |
| the period spanning 2004-2008. | | | | Threats 48 |
| The cardiovascular segment was the market's most | | | | Recent developments 48 |
| lucrative in 2008, generating total revenues of $121.7 | | | | Sanofi-Aventis 50 |
| billion, equivalent to 19.8% of the market's overall value. | | | | Company overview 50 |
| The performance of the market is forecast to | | | | Business description 50 |
| decelerate, with an anticipated CAGR of 3.6% for the | | | | SWOT analysis 50 |
| five-year period 2008-2013, which is expected to drive | | | | Strengths 50 |
| the market to a value of $734 billion by the end of | | | | Weaknesses 52 |
| 2013. | | | | Opportunities 53 |
| Reasons to Purchase | | | | Threats 54 |
| *Save time, money and resources on analyzing the | | | | Recent developments 55 |
| top 10 pharmaceutical companies using this report | | | | AstraZeneca 57 |
| *Analyze the global pharmaceutical market with key | | | | Company overview 57 |
| industry metrics including market value, market volume, | | | | Business description 57 |
| and growth forecasts | | | | SWOT analysis 58 |
| *Assess the intensity of competition based on the | | | | Strengths 58 |
| 5-forces model including degree of rivalry, substitutes, | | | | Weaknesses 59 |
| new entrants, buyer power and supplier power | | | | Opportunities 60 |
| Table of Contents : | | | | Threats 62 |
| FIGURES 3 | | | | Recent developments 62 |
| Tables 4 | | | | Abbott Laboratories 64 |
| Executive Summary 5 | | | | Company overview 64 |
| Industry analysis 5 | | | | Business description 64 |
| Industry definition 5 | | | | SWOT analysis 65 |
| Research highlights 5 | | | | Strengths 65 |
| Top 10 companies landscape 5 | | | | Weaknesses 66 |
| Market value 7 | | | | Opportunities 67 |
| Market forecast 8 | | | | Threats 67 |
| Market segmentation-product 9 | | | | Recent developments 68 |
| Market segmentation-geographic 10 | | | | Merck & Co., Inc. 70 |
| Five Forces Analysis 11 | | | | Company overview 70 |
| Summary 11 | | | | Business description 70 |
| Buyer power 12 | | | | SWOT analysis 71 |
| Supplier power 13 | | | | Strengths 71 |
| New entrants 14 | | | | Weaknesses 71 |
| Substitutes 15 | | | | Opportunities 72 |
| Rivalry 16 | | | | Threats 74 |
| Top 10 Companies Landscape 17 | | | | Recent developments 74 |
| Overview 17 | | | | Wyeth 77 |
| Pfizer 18 | | | | Company overview 77 |
| GlaxoSmithKline 18 | | | | Business description 77 |
| F, Hoffmann-La Roche 19 | | | | SWOT analysis 78 |
| Novartis 19 | | | | Strengths 78 |
| Sanofi-Aventis 19 | | | | Weaknesses 78 |
| AstraZeneca 19 | | | | Opportunities 79 |
| Abbott Laboratories 19 | | | | Threats 79 |
| Merck & Co. 19 | | | | Recent developments 79 |
| Wyeth 20 | | | | Bristol-Myers Squibb Company 82 |
| Bristol-Myers Squibb Company 20 | | | | Company overview 82 |
| Revenue analysis 21 | | | | Business description 82 |
| Financial performance analysis 23 | | | | SWOT analysis 83 |
| Operating profit analysis 24 | | | | Strengths 83 |
| Net profit analysis 25 | | | | Weaknesses 84 |
| Ratio analysis 26 | | | | Opportunities 84 |
| Company Reports 28 | | | | Threats 85 |
| Pfizer Inc 28 | | | | Recent developments 86 |
| Company overview 28 | | | | Five Year Financial Information 88 |
| Business description 28 | | | | Pfizer 88 |
| SWOT analysis 29 | | | | GlaxoSmithKline 91 |
| Strengths 29 | | | | F. Hoffman-La Roche 94 |
| Weaknesses 29 | | | | Novartis 97 |
| Opportunities 30 | | | | Sanofi-Aventis 100 |
| Threats 31 | | | | AstraZeneca 103 |
| Recent developments 32 | | | | Abbott Laboratories 106 |
| GlaxoSmithKline Plc 34 | | | | Merck & Co. |
| Company overview 34 | | | | |